Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos productos contra la periodontitis de mascotas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOPL20141028002
Publicado:
31/12/2015
Caducidad:
15/05/2016
Resumen:
Una empresa polaca está desarrollando un producto de prevención y tratamiento de la periodontitis en mascotas. El producto se encuentra en fase de desarrollo y está disponible en forma de mordedor para perros o producto crujiente para perros y gatos. El principio activo es seguro y efectivo contra bacterias patógenas bucales y su aplicación permite la recuperación de las encías. Se buscan socios industriales con el fin de establecer acuerdos de investigación, licencia, joint venture y financiación.

Details

Tittle:
New anti-periodontitis health products for pets
Summary:
The company from Poland is looking for Research cooperation agreement on development of new form of the products for periodontitis prevention and therapy. The license agreement and/or joint venture is considerable as well. Product is in development phase and may exists i.e. in a form of a "teether" for dogs or a "crisp" for dogs and cats. The active ingredient is safe and effective against mouth pathogenic bacteria and its application leads to gum recovery, periodontitis therapy and may prevent
Description:
The active ingredient is effective against extracellular cysteine peptidases (gingapaines) secreted to mouth by pathogenic bacteria: eg. Porphyromonas gingivalis, Trepanoma denticola, Tanerella forsythia, and Agregatibacter actinomycetemcomitans. Reduction of gingapain level lead in several weeks to gum recovery, periodontitis therapy and finally prevent from many systemic diseases. [eg. Imamura T. 2003 The role of gingapaines in the pathogenesis of periodontal disease. J Periodontol. 74, 111-118].

The preparation may be applied to the dogs in a form of "tether" of "crisps". The form of a "crisps" may be used for application the active ingredient to the cats as well. Both of the forms of an application may support "mechanical" brushing of the teeth, while the active ingredient is acting on plaque, infected gums, and tongue on "biochemical" way. The active ingredient acts with gingapaines leading to their inhibition.

Final version of product, size, hardness, and active ingredient´ concentration have to be determined.

The active ingredient preparation is composed of ovocystatine (OCT), water, and stabilizing agent.
Advantages and Innovations:
The product is based on the innovative active agent - ovocystatin - which is safe for application - do not lead to side effects (like other anti-gingapain agents eg. chlorhexidine [Kolahi J, Ghalayani P, Varshosaz J. (2006): Systemic toxicity following ingestion of the chlorhexidine gluconate solution: a case report. J Int Acad Periodontol. 8, 45-46]. This attribute is critical in pets periodontitis therapy and prevention because pets typically swallow the preparations.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Ovocystatin isolation is protected by procedure submitted for patent (European Patent).

Partner sought

Type and Role of Partner Sought:
Industrial partner interested in development and commercialization of the products is sought. The most preferential models of partnership are:
1. Research cooperation agreement - The client is looking for partner to common product development, and then to common commercialization.
2. License agreement - license for production of the preparation / preparations on the base of the client´s technology (The client company may delivery the active ingredient solution or lyophilisate, or license the technology of active compound production);
3. Joint venture agreement - establishment of the new company responsible for product development and commercialization.
And (4.) Financial agreement - sectorial investor is sought as well. All investments circumstances are negotiable.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
07001002 Ganadería / labranza
07001009 Medicina veterinaria